Last reviewed · How we verify

Q-Roxin (BALOFLOXACIN)

Choongwae · FDA-approved active Small molecule ✓ Verified May 2026 Quality 0/100

Q-Roxin (generic name: BALOFLOXACIN) is a balofloxacin Small molecule drug developed by Choongwae. It is currently FDA-approved.

Q-Roxin is a small molecule. It is also known by the synonyms BALOFLOXACIN, BALOFLOXACINE, and BALOFLOXACINO.

At a glance

Generic nameBALOFLOXACIN
SponsorChoongwae
Drug classbalofloxacin
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Q-Roxin

What is Q-Roxin?

Q-Roxin (BALOFLOXACIN) is a balofloxacin drug developed by Choongwae.

Who makes Q-Roxin?

Q-Roxin is developed and marketed by Choongwae (see full Choongwae pipeline at /company/choongwae).

What is the generic name of Q-Roxin?

BALOFLOXACIN is the generic (nonproprietary) name of Q-Roxin.

What drug class is Q-Roxin in?

Q-Roxin belongs to the balofloxacin class. See all balofloxacin drugs at /class/balofloxacin.

What development phase is Q-Roxin in?

Q-Roxin is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing